25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

Lipplaa, Astrid; Fernandes, Ricardo; Marshall, Andrea; Lorigan, Paul; Dunn, Janet A.; Myers, Kevin A.; Barker, Emily; Newton-Bishop, Julia; Middleton, Mark R.; Corrie, Pippa

doi:10.1038/s41416-018-0179-6

Cited by 14 publications

(8 citation statements)

References 41 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent studies confirmed that a lower vitamin D level was related to greater progression of melanoma [Breslow thickness, Clark level, the American Joint Committee on Cancer (AJCC) stage], the presence of poor prognostic markers (ulceration, higher mitotic index), shorter overall survival and increased risk for melanoma-specific death (222)(223)(224)(225)(226). However, some investigators (227) did not observe such relationships and found only longer disease-free survival for patients with higher vitamin D levels. Melanoma risk is related to a higher number of nevi, however Ribero and coworkers showed positive correlation of serum vitamin D level and nevi count (228).…”

Section: Serum Vitamin D Level In Patients With Melanomamentioning

confidence: 99%

Relevance of Vitamin D in Melanoma Development, Progression and Therapy

2019

View full text Add to dashboard Cite

Melanoma is one of the most lethal types of skin cancer, with a poor prognosis once the disease enters metastasis. The efficacy of currently available treatment schemes for advanced melanomas is low, expensive, and burdened by significant side-effects. Therefore, there is a need to develop new treatment options. Skin cells are able to activate vitamin D via classical and non-classical pathways. Vitamin D derivatives have anticancer properties which promote differentiation and inhibit proliferation. The role of systemic vitamin D in patients with melanoma is unclear as epidemiological studies are not definitive. In contrast, experimental data have clearly shown that vitamin D and its derivatives have anti-melanoma properties. Furthermore, molecular and clinicopathological studies have demonstrated a correlation between defects in vitamin D signaling and progression of melanoma and disease outcome. Therefore, adequate vitamin D signaling can play a role in the treatment of melanoma. Skin cells are able to activate vitamin D via classical and nonclassical metabolic pathways (1-9). Vitamin D derivatives have anticancer properties and promote differentiation and inhibit proliferation of various cells, including melanoma, the most aggressive and lethal type of skin cancer. In this review, we provide an overview on the endogenous synthesis and activation of vitamin D via classical and non-classical pathways. We also present the association of vitamin D and melanoma based on epidemiological, experimental and clinical evidence, showing that defects in vitamin D signaling correlate with progression of melanoma and disease outcome. Therefore, restoration of the adequate vitamin D signaling can play a role in melanoma therapy. 473 This article is freely accessible online.

show abstract

Section: Serum Vitamin D Level In Patients With Melanomamentioning

confidence: 99%

Relevance of Vitamin D in Melanoma Development, Progression and Therapy

2019

View full text Add to dashboard Cite

show abstract

“…Thus, several studies have shown that vitamin D deficiency impairs the macrophage and/or NK cell-mediated cytotoxicity of Rituximab (anti-CD20) in diffuse large B-cell, follicular, and Burkitt lymphoma patients [ 288 , 290 , 291 ], and of Cetuximab (anti-EGFR) in colon cancer cell lines [ 292 ]. In addition, some evidence of benefit has been observed in breast cancer patients treated with Trastuzumab (anti-HER2) and in melanoma patients treated with Bevacizumab (anti-VEGF) [ 290 , 293 ].…”

Section: Mechanisms Introductionmentioning

confidence: 99%

Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms

2022

View full text Add to dashboard Cite

This is a narrative review of the evidence supporting vitamin D’s anticancer actions. The first section reviews the findings from ecological studies of cancer with respect to indices of solar radiation, which found a reduced risk of incidence and mortality for approximately 23 types of cancer. Meta-analyses of observational studies reported the inverse correlations of serum 25-hydroxyvitamin D [25(OH)D] with the incidence of 12 types of cancer. Case-control studies with a 25(OH)D concentration measured near the time of cancer diagnosis are stronger than nested case-control and cohort studies as long follow-up times reduce the correlations due to changes in 25(OH)D with time. There is no evidence that undiagnosed cancer reduces 25(OH)D concentrations unless the cancer is at a very advanced stage. Meta-analyses of cancer incidence with respect to dietary intake have had limited success due to the low amount of vitamin D in most diets. An analysis of 25(OH)D-cancer incidence rates suggests that achieving 80 ng/mL vs. 10 ng/mL would reduce cancer incidence rates by 70 ± 10%. Clinical trials have provided limited support for the UVB-vitamin D-cancer hypothesis due to poor design and execution. In recent decades, many experimental studies in cultured cells and animal models have described a wide range of anticancer effects of vitamin D compounds. This paper will review studies showing the inhibition of tumor cell proliferation, dedifferentiation, and invasion together with the sensitization to proapoptotic agents. Moreover, 1,25-(OH)2D3 and other vitamin D receptor agonists modulate the biology of several types of stromal cells such as fibroblasts, endothelial and immune cells in a way that interferes the apparition of metastases. In sum, the available mechanistic data support the global protective action of vitamin D against several important types of cancer.

show abstract

“…Pre-treatment with vitamin D analogues potentiates TNF-α cytotoxic effects through impaired cell viability as well as DNA fragmentation (26). Synergism has also been reported between vitamin D and tamoxifen (42), histone deacetylase inhibitors (43), paclitaxel (44), dacarbazine and cisplatin (45), 5-fluorouracil (5-FU) (46), bevacizumab (47), immune checkpoint inhibitors (48), and the nutraceutical S-adenosylmethionine (SAM).…”

Section: Resultsmentioning

confidence: 99%

Newly-identified Pathways Relating Vitamin D to Carcinogenesis: A Review

Bilani

Elson

Szuchan

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background: The epidemiological relationship between vitamin D levels and cancer has been thoroughly investigated. Published data from large studies appear to corroborate a significant relationship between higher serum vitamin D concentrations and improved survival. Mechanistic reviews on commonly-studied cancers -including breast cancer, colon cancer and melanoma -focus predominantly on data from older studies. In outlining avenues for future research, we believe there is utility in summarizing novel findings introduced to the literature. Materials and Methods: In this narrative review, we used MEDLINE, PUBMED and Cochrane databases to identify mechanistic studies published from January 1, 2015 onwards exploring this topic. Results: Twenty-five mechanistic studies were included in this review. It was found that vitamin D plays a critical role in both direct (i.e. tumor gene expression, proliferation, invasiveness, sensitivity to chemotherapy etc.) and indirect (i.e. effects on the tumor microenvironment and immunomodulation) tumor suppression mechanisms. Conclusion: These newly-identified pathways warrant further research, with the hopes that we may understand how and when vitamin D supplementation can be integrated into precision medicine therapeutics for cancers of the breast, colon and skin. Cancer care providers should consider recommendations to screen for vitamin D deficiency in this population.

show abstract

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

Abstract: In this stage II/III melanoma cohort, vitamin D did not correlate with known prognostic markers, nor predict for DFI or OS, but there was some evidence of benefit for patients with stage II disease treated with bevacizumab.

Cited by 14 publications

References 41 publications

Relevance of Vitamin D in Melanoma Development, Progression and Therapy

Relevance of Vitamin D in Melanoma Development, Progression and Therapy

Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms

Newly-identified Pathways Relating Vitamin D to Carcinogenesis: A Review

Contact Info

Product

Resources

About